Ignite Creation Date:
2025-12-25 @ 12:16 AM
Ignite Modification Date:
2026-01-04 @ 3:39 PM
Study NCT ID:
NCT06590558
Status:
WITHDRAWN
Last Update Posted:
2025-07-03
First Post:
2024-09-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Sponsor:
National Cancer Institute (NCI)
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-08-04
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-05-17
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-05-17
Completion Date Type:
ESTIMATED
First Submit Date:
2024-09-06
First Submit QC Date:
None
Study First Post Date:
2024-09-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-02
Last Update Post Date:
2025-07-03
Last Update Post Date Type:
ACTUAL